Pharma veteran with over three decades of industry experience to lead Alembic’s animal health growth and market expansion initiatives.
This collaboration across the NIPER network- Raebareli, Hajipur, Ahmedabad and Hyderabad is strengthening translational research and opnMe access
Combined company targets Rs. 2,500–3,000 crore revenue by 2030; new sterile and OSD plants to begin operations by August 2026
Doshi has established a strong track record in driving quality assurance, regulatory compliance, and formulation excellence across complex pharmaceutical operations
The global pharmaceutical company has been featured in both the DJBIC World Index and the DJBIC Emerging Markets Index
US formulations grew 11% to Rs. 564 crore as Alembic enters US branded pharmaceuticals market with launch of Pivya
Ex-US revenue rose sharply by 21% YoY to Rs. 2, 240.4 crore ($254 million); Operational PAT grew 50.3% YoY to Rs. 518.1 crore
The certification follows an inspection conducted by the Malta Medicines Authority between January 29, 2026, and February 3, 2026
Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States
The company reported a 108% rise in profit after tax, driven by strong growth in regulated markets, branded generics, and U.S. expansion initiatives
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
